We have designed peptide-antagonists that are capable of disrupting growth factor:ECM interactions, reducing activation of signaling cascades downstream of IGF-I and providing anti-tumor effects in in vitro breast cancer models12. This evidence concerns the gene IGF1 and neoplasm.